HOME >> BIOLOGY >> NEWS
Scientists discover two-component lantibiotic with therapeutic potential

CHAMPAIGN, Ill. -- The discovery and preparation of a naturally occurring antibiotic could open the door to new therapeutic drugs for treating nasty infections.

The rapid spread of drug-resistant bacterial strains poses a persistent threat to human health, and requires new sources of antibiotics to treat infections. Researchers at the University of Illinois at Urbana-Champaign are tackling this problem by discovering and preparing natural antibiotics called lantibiotics.

Lantibiotics are a class of very potent antimicrobial compounds whose antimicrobial properties are attributed to their structure. They possess unusual sulfur bridged rings that provide structural rigidity for binding their cellular targets. Lantibiotics are commonly used in the food industry to inhibit the growth of microorganisms.

"Having the ability to make analogs of these naturally occurring antibiotics gives us the flexibility to look for improvements in properties such as toxicity, biostability and bioavailability," said Wilfred van der Donk, a William H. and Janet Lycan Professor of Chemistry at the U. of I. He is a corresponding author of a paper that will be posted online this week ahead of regular publication by the Proceedings of the National Academy of Sciences. In previous work, van der Donk first identified the molecular activity of an enzyme (LctM) responsible for naturally turning a small protein into a lantibiotic. That discovery, reported in the journal Science in 2004, involved lacticin 481, a lantibiotic produced by several strains of Lactococcus lactis, a bacterium used in cheese production.

In March 2006, van der Donk's team reported, again in Science, the synthesis of the lantibiotic nisin. The most studied lantibiotic, nisin has been used as a food preservative for more than 40 years without the development of significant antibiotic resistance.

Then, in the Oct. 26 issue of Chemistry and Biology, the team demonstrated that LctM could accept subst
'"/>

Contact: James E. Kloeppel
kloeppel@uiuc.edu
217-244-1073
University of Illinois at Urbana-Champaign
30-Oct-2006


Page: 1 2 3

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Scientists prove that disputed Korean stem cell line comes from an unfertilized egg and not cloning
3. Scientists move closer to bio-engineered bladders
4. Scientists find stem cell switch
5. Scientists discover new way to study nanostructures
6. Scientists a step closer to understanding how anaesthetics work in the brain
7. Scientists to make news at Computational Biology Conference
8. Accident-prone? Scientists link brain function to knee injuries
9. Scientists take next step in understanding potential target for ovarian cancer treatment
10. Scientists find brown fat master switch
11. Scientists identify 2 distinct Parkinsons networks

Post Your Comments:
(Date:3/12/2015)... 12, 2015 Beta Systems ... and access management (IAM) solution for a fixed ... Beta System,s new IAM package, customers benefit from ... from multiple IAM implementations across different industries. The ... well as any necessary services and consulting. It ...
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
(Date:3/25/2015)... 26, 2015 Agnition announced today that ... American Farmer, airing for the first time at 7:30 ... American Farmer will explore the extremely important role soil ... with a patented Microbial Catalyst™ technology that enhances soil ... The segment will air again on April 28. , ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 Laboratory ... Top-Loading Balances and Analytical Balances to get best-performing ... line of weighing balances from the trusted brand ... Balances increase your efficiency by providing a ... of samples. Weighing modes include parts counting, percent ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
Cached News: